Study Evaluating Venetoclax in Subjects With Hematological Malignancies

NCT02265731 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma (NHL)
Multiple Myeloma (MM)
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Acute Myeloid Leukemia (AML)

Interventions

DRUG: azacitadine
DRUG: venetoclax
DRUG: rituximab / IDEC-C2B8
DRUG: rituximab / IDEC-C2B8

Sponsor

AbbVie

Collaborators

[object Object]